Ratings by Goldman Sachs (Chris Shibutani)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/1/2025 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2025 | United Therapeutics Corp. | UTHR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2025 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2025 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/13/2025 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2025 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2025 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2025 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 1/14/2025 | Schrodinger | SDGR | Maintain | Neutral (N/A) |
|
Details | ||
| 12/20/2024 | Vaxcyte | PCVX | New Coverage | Buy (N/A) |
86.62 (33.06) |
-61.83% | Details | |
| 12/16/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2024 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2024 | BioNTech | BNTX | Upgrade | Buy (Neutral) |
106.64 (97.53) |
-8.54% | Details | |
| 11/6/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2024 | United Therapeutics Corp. | UTHR | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2024 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 10/25/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 10/25/2024 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2024 | Exelixis | EXEL | Maintain | Sell (N/A) |
|
Details | ||
| 9/27/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2024 | Schrodinger | SDGR | Maintain | Neutral (N/A) |
|
Details | ||
| 9/16/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2024 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2024 | United Therapeutics Corp. | UTHR | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2024 | Inova Technology, Inc. | INVA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2024 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 7/26/2024 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 6/7/2024 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/30/2024 | Johnson & Johnson | JNJ | New Coverage | Neutral (N/A) |
144.44 (263.04) |
82.11% | Details | |
| 5/28/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2024 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2024 | United Therapeutics Corp. | UTHR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2024 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2024 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 2/29/2024 | Schrodinger | SDGR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/20/2024 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/20/2024 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2024 | United Therapeutics Corp. | UTHR | Upgrade | Neutral (Sell) |
211.74 (555.91) |
162.54% | Details | |
| 2/5/2024 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2024 | Merck | MRK | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 1/30/2024 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 1/25/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2024 | Revance Therapeutic | RVNC | Downgrade | Neutral (Buy) |
7.05 (3.65) |
-48.23% | Details | |
| 12/15/2023 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2023 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2023 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/12/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2023 | Abbvie | ABBV | Upgrade | Buy (Neutral) |
149.28 (261.07) |
74.89% | Details | |
| 11/3/2023 | Organon & Co. | OGN | Downgrade | Neutral (Buy) |
13.11 (13.55) |
3.36% | Details | |
| 11/3/2023 | Seres Therapeutics | MCRB | Maintain | Sell (N/A) |
|
Details | ||
| 11/1/2023 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/13/2023 | Arcutis Biotherapeutics Inc. | ARQT | Downgrade | Neutral (Buy) |
4.51 (25.81) |
472.28% | Details | |
| 10/11/2023 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
12.50 (8.75) |
-30% | Details | |
| 9/21/2023 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2023 | Schrodinger | SDGR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2023 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2023 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2023 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | EQRx, Inc. | EQRX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2023 | Repare Therapeutics | RPTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2023 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/14/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2023 | Inova Technology, Inc. | INVA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2023 | Revolution | RVMD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2023 | Nektar Therapeutics | NKTR | Maintain | Sell (N/A) |
|
Details | ||
| 2/24/2023 | Erasca Inc | ERAS | New Coverage | Buy (N/A) |
3.65 (18.47) |
406.03% | Details | |
| 2/17/2023 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2023 | Prometheus Biosciences Inc | RXDX | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/19/2022 | Schrodinger | SDGR | New Coverage | Buy (N/A) |
19.89 (19.30) |
-2.97% | Details | |
| 12/19/2022 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
33.45 (14.00) |
-58.15% | Details | |
| 12/13/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2022 | Pfizer | PFE | Upgrade | Buy (Neutral) |
52.16 (24.32) |
-53.37% | Details | |
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Buy (N/A) |
|
Details | ||
| 12/5/2022 | United Therapeutics Corp. | UTHR | New Coverage | Sell (N/A) |
275.61 (211.74) |
-23.17% | Details | |
| 11/17/2022 | Exscientia PLC | EXAI | Maintain | Buy (Buy) |
|
Details | ||
| 11/11/2022 | EQRx, Inc. | EQRX | Downgrade | Neutral (Buy) |
3.89 (2.34) |
-39.85% | Details | |
| 11/9/2022 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Entrada Therapeutics | TRDA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2022 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/27/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Buy (N/A) |
|
Details | ||
| 9/22/2022 | Revance Therapeutic | RVNC | New Coverage | Buy (N/A) |
25.80 (3.65) |
-85.85% | Details | |
| 9/8/2022 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/15/2022 | Entrada Therapeutics | TRDA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/12/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2022 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
21.48 (113.51) |
428.45% | Details | |
| 7/20/2022 | Inova Technology, Inc. | INVA | New Coverage | Neutral (N/A) |
14.51 (19.03) |
31.15% | Details | |
| 7/20/2022 | Prometheus Biosciences Inc | RXDX | New Coverage | Buy (N/A) |
29.29 (199.92) |
582.55% | Details | |
| 7/6/2022 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/13/2022 | EQRx, Inc. | EQRX | New Coverage | Buy (N/A) |
4.10 (3.89) |
-5.12% | Details | |
| 6/6/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2022 | Entrada Therapeutics | TRDA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/27/2022 | Organon & Co. | OGN | New Coverage | Buy (N/A) |
31.66 (13.55) |
-57.2% | Details | |
| 4/27/2022 | Royalty Pharma | RPRX | New Coverage | Buy (N/A) |
41.83 (35.25) |
-15.73% | Details | |
| 4/20/2022 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 4/20/2022 | Alkermes | ALKS | New Coverage | Buy (N/A) |
28.48 (54.58) |
91.64% | Details | |
| 4/18/2022 | Nektar Therapeutics | NKTR | Downgrade | Sell (Neutral) |
6.16 (71.04) |
1053.25% | Details | |
| 4/1/2022 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Neutral (Buy) |
14.93 (18.27) |
22.37% | Details | |
| 3/31/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/29/2022 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2022 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Buy (N/A) |
15.98 (25.81) |
61.51% | Details | |
| 3/17/2022 | Repare Therapeutics | RPTX | New Coverage | Buy (N/A) |
12.12 (2.65) |
-78.14% | Details | |
| 3/1/2022 | Revolution | RVMD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2022 | Neurocrine Bio. | NBIX | Upgrade | Buy (Neutral) |
85.55 (128.74) |
50.49% | Details | |
| 2/7/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2022 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
20.00 (14.93) |
-25.35% | Details | |
| 1/26/2022 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 12/17/2021 | Pfizer | PFE | New Coverage | Neutral (N/A) |
61.25 (24.32) |
-60.29% | Details | |
| 12/17/2021 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
131.78 (261.07) |
98.11% | Details | |
| 12/17/2021 | Eli Lilly | LLY | New Coverage | Neutral (N/A) |
279.04 (1213.91) |
335.03% | Details | |
| 12/17/2021 | Johnson & Johnson | JNJ | New Coverage | Neutral (N/A) |
173.01 (144.44) |
-16.51% | Details | |
| 12/17/2021 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (N/A) |
62.17 (58.13) |
-6.5% | Details | |
| 12/17/2021 | Merck | MRK | New Coverage | Conviction Buy (N/A) |
75.91 (129.56) |
70.68% | Details | |
| 11/23/2021 | Entrada Therapeutics Inc. | TRDA | New Coverage | Neutral (N/A) |
32.79 (5.06) |
-84.57% | Details | |
| 11/11/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/2/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2021 | Exscientia PLC | EXAI | New Coverage | Buy (N/A) |
22.20 (4.84) |
-78.2% | Details | |
| 9/7/2021 | Tango Therapeutics Inc. | TNGX | New Coverage | Buy (N/A) |
12.00 (29.46) |
145.5% | Details | |
| 8/12/2021 | Revolution | RVMD | Downgrade | Neutral (Buy) |
26.90 (189.24) |
603.49% | Details | |
| 8/11/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/23/2021 | Seres Therapeutics | MCRB | Downgrade | Sell (Neutral) |
20.83 (7.74) |
-62.84% | Details | |
| 5/18/2021 | Exelixis | EXEL | New Coverage | Sell (N/A) |
25.24 (39.01) |
54.56% | Details | |
| 5/18/2021 | Seres Therapeutics | MCRB | New Coverage | Neutral (N/A) |
21.80 (7.74) |
-64.5% | Details | |
| 5/18/2021 | Neurocrine Bio. | NBIX | New Coverage | Neutral (N/A) |
93.08 (85.55) |
-8.09% | Details | |
| 5/18/2021 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
18.19 (71.04) |
290.54% | Details | |
| 5/18/2021 | BioNTech | BNTX | New Coverage | Neutral (N/A) |
198.30 (97.55) |
-50.81% | Details | |
| 5/18/2021 | Revolution | RVMD | New Coverage | Buy (N/A) |
31.48 (189.24) |
501.14% | Details | |
| 5/18/2021 | Arena Pharma | ARNA | New Coverage | Buy (N/A) |
60.89 (99.98) |
64.2% | Details |
